Overview

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% in subjects with Netherton Syndrome (NS) in comparison to vehicle
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Quoin Pharmaceuticals